Skip to Main Content
Our Commitment to Diversity


Whitney J. Smith

Represented FUJIFILM Holdings America Corporation and FUJIFILM Electronics Materials U.S.A., Inc. in the acquisition of a semiconductor high-purity process chemicals (HPPC) business from US-based Entegris, Inc. HPPCs are used to etch and clean silicon wafers in the production of semiconductors and are a growing segment of materials used in semiconductor production. The target company, CMC Materials KMG Corporation, has chemical manufacturing facilities in the United States, United Kingdom, France, Italy, and Singapore. FUJIFILM Electronics Materials is a supplier of advanced technology, chemistry, and delivery equipment to the semiconductor and flat-panel display fabrication market headquartered in North Kingstown, Rhode Island. The acquisition is subject to customary closing conditions, including regulatory approvals.
Represented Pharmaceutical Associates, Inc. in connection with its acquisition of Vertice Pharma, LLC and its subsidiary VistaPharm, and the simultaneous sale of business assets from Vertice to a third-party buyer. South Carolina-based Pharmaceutical Associates manufactures and markets generic liquid pharmaceuticals in standard bottle packaging and ready-to-dispense packaging. Vertice is a generic pharmaceutical company with headquarters in New Jersey and manufacturing operations in Florida.
Represented Endo International plc (NASDAQ: ENDP), and its subsidiary Endo Ventures Limited, in the acquisition of six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc.
Represented Lake Capital and its portfolio company Engine Group, a New York-based media and marketing services company, in the sale of its Trailer Park business. Trailer Park is headquartered in Hollywood, CA and in the business of developing, producing and delivering movie trailers and other content marketing campaigns for studios, networks, entertainment streaming and technology companies, and consumer brands.
Represented Teligent, Inc. (OTCMKTS: TLGTQ) and its subsidiaries in the auction and sale of substantially all of Teligent's assets in three simultaneous sale transactions under Section 363 of the Bankruptcy Code. Teligent sold its U.S. pharmaceutical manufacturing facility to Leiters, Inc.; its U.S. pharmaceutical marketing authorizations to PAI Holdings, LLC; and its Canadian pharmaceutical distribution business to Hikma Canada Limited. New Jersey-based Teligent, Inc. is a specialty generic pharmaceutical company.
Represented Erie Street Companies, a strategic and operational growth advisory firm based in Chicago, Illinois, and its portfolio company Trailer Park Group, in connection with Trailer Park's acquisition of MXW Studios Limited, a London, United Kingdom-based creative and strategic marketing company providing services to clients in the entertainment industry.
Represented Endo International PLC (NASDAQ: ENDP), an American Irish-domiciled generics and specialty branded pharmaceutical company, and its subsidiary Par Pharmaceutical, Inc. in the sale of its manufacturing facility in Chestnut Ridge, New York and a basket of ANDAs to Strides Pharma Science. The facility has an annual capacity of 2 billion units across semisolids, liquids, nasal sprays along with oral solids and is registered with the Drug Enforcement Administration (DEA) enabling manufacturing of controlled substances.
Represented consumer finance company OneMain Financial in its acquisition of Trim, a financial wellness company based in California that empowers customers across the United States to manage their financial goals by negotiating bills, analyzing transaction data, and enabling automated savings.
Represented Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, in connection with the issuance of approximately US$27.5 million aggregate principal amount of Series D Zero Coupon Convertible Senior Notes due 2023. The new Series D Convertible Notes were issued in exchange for approximately US$57.9 million in aggregate principal amount, plus accrued but unpaid interest, of the company’s outstanding 4.75 percent Series A Convertible Senior Notes due May 2023, which gave effect to a 52.5 percent discount on the principal amount of Series A Convertible Notes exchanged.
Represented Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, in a series of strategic actions to enhance the company's financial flexibility. To reduce leverage, the company worked with its senior lender and Series C Convertible Noteholders to convert US$77 million of debt into a combination of common and preferred stock. The lenders also provided an additional US$4.6 million of availability under the company's second lien credit facility. Upon consummating the debt conversion and incremental debt financing, the company launched an at-the-market equity offering seeking to raise an additional US$22.6 million.

Represented a U.S. pharmaceutical manufacturer in connection with its bid to acquire a sterile injectable business and its affiliate, a Bangalore, India-based CDMO listed on the Bombay Stock Exchange. The deal terminated due to lack of timely regulatory approval.

Represented Par Pharmaceuticals in its acquisition of Innoteq, a developer and manufacturer of transdermal patch and thin film pharmaceutical products.

Represented a U.S. pharmaceutical manufacturer in its acquisition of an India-based R&D pharmaceutical company.

Represented Par Pharmaceuticals in connection with the divestiture of its North Carolina and Alabama manufacturing facilities and related generic pharmaceutical products.

Represented a U.S. pharmaceutical manufacturer in its acquisition of an India-based developer and manufacturer of API.

Represented a pharmaceutical manufacturer in its acquisition of a contract research organization that provides bioavailability and bioequivalence studies.

Advised NYSE-listed company in connection with a significant restatement of past financial statements and related SEC and NYSE inquiries.

Acquisition of a basket of 14 products in an FTC-mandated divestiture related to Watson Pharmaceuticals’ acquisition of Actavis.
Represented Erie Street Capital in its acquisition (together with its acquisition partner PSP Capital Partners) of 3Q Digital, a performance & digital marketing agency.
Represented Erie Street Consulting in its acquisition of Performance Improvement Partners, a business process and IT management solutions firms serving PE firms and their portfolio companies.
Represented speciality pharmaceutical company Mayne Pharma in its acquisition of six branded foam dermatology products from GSK.
Represented Mayne Pharma in its acquisition of 42 generic products in an FTC-mandated divestiture related to Teva’s acquisition of Allergan’s generic pharmaceutical business.
Represented Engine Group, a portfolio company of Lake Capital, in its acquisition of bRealTime, a supply-side digital advertising technology company that helps publishers monetize inventory through real-time bidding exchanges.
Represented Engine Group, a portfolio company of Lake Capital, in its acquisition of, a demand-side digital advertising technology company.
Represented Engine Group, a portfolio company of Lake Capital, in its acquisition of Balihoo, a provider of digital advertising technology enabling national brands to execute hyper-local campaigns.
Represented a Canadian company with operations in Uruguay that possesses one of the first government licenses to grow and export medical cannabis in Uruguay in its international corporate structuring and Series A and Series B equity financings.
Represented Crane Co., a diversified manufacturer of industrial products, in its acquisition of Westlock Controls, a manufacturer of switchboxes, position transmitters and other solutions for networking, monitoring and controlling process valves.
Represented VitAg, a company that had developed technology to manufacture fertilizer from biosolids, in its management buyout and subsequent restructuring involving an equity investment by TPG, a tax-exempt bond offering, a credit facility and a real estate purchase for the purpose of constructing and commissioning its first biosolids-to-fertilizer plant.
Represented Solvay, a global chemical company, in the divestiture of its formulated resins business.
Represented the London Stock Exchange Group in its acquisition of, a publicly traded U.S. broker-dealer.
Represented Wilson Towers Watson in its divestiture of multiple offices and insurance brokerage businesses.
Advised Artesyn Technologies, a power solutions company listed on Nasdaq, and its Board of Directors in connection with an unsolicited proposal to merge the company and subsequently in connection with negotiations with an activist hedge fund that had acquired a 10% stake in the company.
Represented Philips in its acquisition of Raytel Medical Corporation, a U.S. remote cardiac monitoring company from an Israeli telemedicine company.
Represented Philips in its acquisition of Lighting Technologies International, a specialty lighting company
Represented Philips in its acquisition of Digital Lifestyle Outfitters, an electronics peripherals and accessories distribution company.
Represented generic pharmaceutical company Teligent in its $34.4 million Series B Senior Convertible Notes offering.
Represented generic pharmaceutical company Teligent in its $50 million Series C Convertible Note Financing and Exchange.
Represented DuPont in its acquisition of a provider of sulfuric acid technology processes and equipment from PE firm American Securities.
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel